The science that led Garuda Therapeutics Inc. to a $62 million series B financing was a combination of hard work, luck and serendipity, according to co-founder and CEO Dhvanit Shah. At the Harvard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback